You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Has dysesthesia been reported in patients taking Zepbound® (tirzepatide)?
In the SURMOUNT-1 and -2 studies, dysesthesia was reported by 0.2%, 0.2%, and 0.4% of participants treated with tirzepatide 5 mg, 10 mg, and 15 mg, respectively. Dysesthesia was reported by 0.1% of participants receiving placebo.
See important safety information, including boxed warning, in the attached prescribing information.
Dysesthesia
Dysesthesia is a touch-based disorder that can result in feelings of pain, itchiness, tingling, shock, burning, and other uncomfortable sensations in the skin.1
In 2 weight reduction trials in adults with obesity or overweight, with or without type 2 diabetes, dysesthesia occurred more frequently among patients receiving tirzepatide (5 mg 0.2%, 10 mg 0.2%, 15 mg 0.4%) than placebo (0.1%).2
Enclosed Prescribing Information
References
1Dysesthesia. Cleveland Clinic. Updated May 12, 2023. Accessed November 13, 2024. https://my.clevelandclinic.org/health/symptoms/24989-dysesthesia
2Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: November 13, 2024